Jump to content

Nebacumab

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Entranced98 (talk | contribs) at 14:21, 26 September 2023 (Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Nebacumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetendotoxin
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]

References

[edit]
  1. ^ Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.
  2. ^ WHO: Consolidated List of Products
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Nebacumab&oldid=1177181643"